Latest News

Transgene: First Patient enrolled in Phase I Trial of TG4023 for the Treatment of Liver Tumours

New Phase IIa data on TMC435 in patients with hepatitis C presented at the ongoing AASLD - meeting

Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009

Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)

IRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM TWO PIVOTAL PHASE 3 TRIALS IN PATIENTS WITH CHRONIC CONSTIPATION

Movetis obtains EU authorisation for the commercialisation of Resolor

SciClone Announces Enrollment of First Patient in Its Phase 2 Trial of SCV-07 in Hepatitis C

Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement for novel oral agent to treat Type II Diabetes

Intercell starts European Pivotal Phase III clinical trial for the patch-based Travelers' Diarrhea Vaccine

ImmunoCellular Therapeutics Announces Successful Humanization of Two Antibody Candidates

More news... | RSS Feed...

Most Viewed

Boston Scientific Announces FDA Clearance and U.S. and European Availability of WallFlex

Intercell starts European Pivotal Phase III clinical trial for the patch-based Travelers' Diarrhea Vaccine

Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement for novel oral agent to treat Type II Diabetes

Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-2125, a TLR9 Agonist, in Combination with Ribavirin for Chronic Hepatitis C Virus Infection

Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference

SciClone Announces Enrollment of First Patient in Its Phase 2 Trial of SCV-07 in Hepatitis C

PTC THERAPEUTICS INITIATES REGISTRATION-DIRECTED PHASE 3 TRIAL OF ATALUREN IN CYSTIC FIBROSIS

ImmunoCellular Therapeutics Announces Successful Humanization of Two Antibody Candidates

FDA Grants Protalix Orphan Drug Designation for prGCD

Data Safety Monitoring Board Unanimously Recommends Continuation of Delcath's Phase III Clinical Trial

Therapeutic Target

Cardiovascular

Dermatology

Endocrine and Metabolic

Gastroenterology

Genitourinary

Hematology

Immunology and Allergy

Infection

Musculoskeletal

Neurology

Obstetrics and Gynecology

Oncology

Ophthalmology

Psychiatry

Pulmonary

Categories

Deals and Alliances

Development

Financial Results

Financings

Intellectual Property

Regulatory

Press releases

Deals review

Headlines

PR Newswire